Assessing Time Tradeoff Utilities in Health States of Organic Hypogonadotropic Hypogonadism: A Pilot Study in Brazil
Author(s)
Afonso Nogueira Simões Correa Neto, MD1, Mariana Andrades Fiorino Monteiro Novo, M.Sc2, Muriel Barros, M.Sc3, Suena Parahiba, M.Sc3, Gilson Dorneles, M.Sc3, Bruna Marmett, M.Sc3, Vania Santos Nunes-Nogueira, PhD, MD4, Julia Simoes Correa Galendi, PhD, MD5.
1Universidade do Estado do Rio de Janeiro (UERJ), Botucatu, Brazil, 2Botucatu Medical School, University of the State of São Paulo (UNESP), Botucatu, Brazil, 3Escritório de Projetos, Hospital Moinhos de Vento, Porto Alegre RS, Brazil, Porto Alegre, Brazil, 4BotucatuMedical School, São Paulo State University (UNESP), Botucatu, Brazil, 5Associate Researcher, Botucatu Medical School, University of the State of São Paulo (UNESP), São Paulo, Brazil.
1Universidade do Estado do Rio de Janeiro (UERJ), Botucatu, Brazil, 2Botucatu Medical School, University of the State of São Paulo (UNESP), Botucatu, Brazil, 3Escritório de Projetos, Hospital Moinhos de Vento, Porto Alegre RS, Brazil, Porto Alegre, Brazil, 4BotucatuMedical School, São Paulo State University (UNESP), Botucatu, Brazil, 5Associate Researcher, Botucatu Medical School, University of the State of São Paulo (UNESP), São Paulo, Brazil.
OBJECTIVES: This study aimed to elicit time trade-off (TTO) utility values for different Organic Hypogonadotropic Hypogonadism (OHH) health states.
METHODS: In this cross-sectional survey, healthy healthcare professionals and medical students in Brazil, were asked to value five different OHH health states from a societal perspective. Data collection was conducted via videoconference. Participants assigned TTO utility values to the vignettes for (1) men with OHH treated with intramuscular testosterone, (2) male adolescents with OHH treated with intramuscular testosterone, (3) untreated men with OHH, (4) untreated male adolescents with OHH, and (5) untreated female adolescents with OHH. Male participants assigned TTO utility values to four male health status (1 to 4) and women only about their health status (5). Vignettes were developed based on literature review and clinical expert consultation. Brazilian population norms (baseline utility of 0.824 from Santos et al. 2021) were considered to calculate utility values. The study’s vignettes and methodology are documented in the Open Science Framework database (https://doi.org/10.17605/OSF.IO/WTBRX).
RESULTS: Thirty-nine participants (51% male, mean age 27.9 ± 7.0 years) completed the interviews. For adolescents (n=20) with untreated HHO, the average utility was 0.24 (SD=0.19), whereas adolescents with HHO treated with intramuscular testosterone had a significantly higher average utility of 0.69 (SD=0.20). For men (n=20) with untreated HHO, the average utility was 0.37 (SD=0.24), and this increased to 0.70 (SD= 0.13) in men who received intramuscular testosterone treatment. For girls (n=19) with untreated HHO had an average utility of 0.23 (SD=0.21).
CONCLUSIONS: This study provides the first evidence that untreated OHH correlates with low utility values (0.23-0.37), while testosterone treatment substantially improves utilities in males (0.69-0.70). Our results suggest that the impact of treatment is significant for improving quality of life in patients with OHH.
METHODS: In this cross-sectional survey, healthy healthcare professionals and medical students in Brazil, were asked to value five different OHH health states from a societal perspective. Data collection was conducted via videoconference. Participants assigned TTO utility values to the vignettes for (1) men with OHH treated with intramuscular testosterone, (2) male adolescents with OHH treated with intramuscular testosterone, (3) untreated men with OHH, (4) untreated male adolescents with OHH, and (5) untreated female adolescents with OHH. Male participants assigned TTO utility values to four male health status (1 to 4) and women only about their health status (5). Vignettes were developed based on literature review and clinical expert consultation. Brazilian population norms (baseline utility of 0.824 from Santos et al. 2021) were considered to calculate utility values. The study’s vignettes and methodology are documented in the Open Science Framework database (https://doi.org/10.17605/OSF.IO/WTBRX).
RESULTS: Thirty-nine participants (51% male, mean age 27.9 ± 7.0 years) completed the interviews. For adolescents (n=20) with untreated HHO, the average utility was 0.24 (SD=0.19), whereas adolescents with HHO treated with intramuscular testosterone had a significantly higher average utility of 0.69 (SD=0.20). For men (n=20) with untreated HHO, the average utility was 0.37 (SD=0.24), and this increased to 0.70 (SD= 0.13) in men who received intramuscular testosterone treatment. For girls (n=19) with untreated HHO had an average utility of 0.23 (SD=0.21).
CONCLUSIONS: This study provides the first evidence that untreated OHH correlates with low utility values (0.23-0.37), while testosterone treatment substantially improves utilities in males (0.69-0.70). Our results suggest that the impact of treatment is significant for improving quality of life in patients with OHH.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE65
Topic
Economic Evaluation, Health Technology Assessment, Medical Technologies
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity)